Loading
Loading
Cytoprotective · Immune-modulatory · Anti-tumour · Recovery support
A growing body of preclinical research examines peptides across three domains of oncology: protecting normal tissue from chemotherapy toxicity, modulating immune responses to cancer, and directly suppressing tumour growth in laboratory models.
Conventional cancer treatment — chemotherapy, radiation, and surgery — remains highly effective but carries significant collateral damage to healthy tissue. Chemotherapy agents that target rapidly dividing cancer cells also destroy gut lining cells, bone marrow progenitors, peripheral nerve fibres, hair follicles, and cardiac tissue. Managing this toxicity is one of the central challenges of modern oncology.
Peptides have attracted research interest for three broad reasons:
Cytoprotection
Protecting normal tissue from chemotherapy and radiation damage — reducing mucositis, neuropathy, cardiotoxicity, and nephrotoxicity
Immune support
Restoring immune function suppressed by chemotherapy — enhancing T-cell, NK cell, and dendritic cell activity against residual tumour cells
Anti-tumour activity
Direct suppression of cancer cell proliferation, induction of apoptosis, and reduction of metastatic signalling in laboratory models
Peptides offer a degree of biological specificity — receptor-level targeting — that small molecules often lack. Their natural counterparts exist in the body's own repair and immune repertoire, making them a rational starting point for research into augmenting the body's response to cancer and its treatment.
The following peptides have been studied in preclinical models for their ability to protect normal tissue during chemotherapy and accelerate recovery afterwards. None are approved for this use.
Body Protection Compound 157
A synthetic pentadecapeptide derived from a protective gastric protein. Extensively studied in rodent models for its ability to heal mucosal tissue, reduce inflammation, and protect organs from drug-induced damage — making it one of the most researched peptides in the context of chemotherapy side-effect mitigation.
Proposed Mechanism
Key Preclinical Findings
Thymosin Beta-4 (synthetic analogue)
TB-500 is a synthetic peptide corresponding to the active region of Thymosin Beta-4, an endogenously produced protein involved in actin polymerisation, angiogenesis, and tissue repair. Preclinical research has examined its potential to accelerate recovery from radiation damage and chemotherapy-induced tissue toxicity.
Proposed Mechanism
Key Preclinical Findings
Copper peptide GHK
GHK-Cu is a naturally occurring tripeptide (Gly-His-Lys) complexed with copper(II) ions, found in human plasma. Concentrations decline sharply with age. Research has explored its roles in wound repair, anti-inflammatory signalling, and — in a more speculative capacity — modulation of genes associated with tumour suppressor pathways.
Proposed Mechanism
Key Preclinical Findings
Chemotherapy is profoundly immunosuppressive. The immune system's natural capacity to detect and destroy residual tumour cells is blunted precisely when it matters most. Immune-modulatory peptides have been studied for their ability to restore lymphocyte function, enhance innate immunity, and potentially synergise with modern immunotherapy approaches.
TA1 / Thymalfasin
Thymosin Alpha-1 is a 28-amino-acid peptide naturally secreted by the thymus gland. It is the most clinically advanced peptide in this class — approved in over 35 countries (including Italy, China, and several Southeast Asian nations) as an immune adjunct in chronic hepatitis B/C and as supportive therapy in oncology. In Australia it is not TGA-approved but is available for research use.
Mechanism of Action
Research Findings
Tuftsin analogue
Selank is a synthetic heptapeptide analogue of tuftsin, a naturally occurring tetrapeptide derived from IgG. Originally developed in Russia as an anxiolytic, it has shown immune-regulatory properties in preclinical research relevant to the chronic stress and immune suppression that accompanies cancer treatment.
Mechanism of Action
Research Findings
Epitalon / Epithalamin
Epithalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from the pineal gland peptide epithalamin. It is one of the few peptides with published data spanning from animal lifespan studies to limited human trials, primarily concerning telomerase activity, ageing, and oncogenesis suppression.
Mechanism
Preclinical Findings
Human cathelicidin antimicrobial peptide
LL-37 is the sole human cathelicidin, constitutively expressed by neutrophils and epithelial cells. It plays dual and often paradoxical roles in cancer biology — acting as a tumour suppressor in some cancer types while promoting proliferation in others — making it an active area of translational oncology research.
Mechanism
Preclinical Findings
Thymosin era
Allan Goldstein's lab at George Washington University characterised the thymosin family of peptides. Thymosin Alpha-1 was first isolated and shown to restore T-cell function in immunodeficient animals — setting the foundation for peptide immunology in oncology.
BPC-157 discovery
Ivan Sikirić's group at Zagreb University published seminal work on the cytoprotective effects of BPC-157 in gastric mucosa models. Early papers identified systemic protective effects beyond the GI tract — a finding later extended to chemotherapy damage models.
First clinical TA1 trials
Published Phase II/III trials from Chinese research groups demonstrated Thymosin Alpha-1 as an adjunct in non-small-cell lung cancer and hepatocellular carcinoma. TA1 (Zadaxin) obtained approvals in multiple Asian and European countries for hepatitis and oncology use.
Genomic and mechanistic expansion
GHK-Cu genomic profiling studies published data suggesting influence over >4,000 human genes. TB-500's cardioprotective role against anthracycline toxicity gained attention in cardio-oncology research. LL-37's dual role in cancer biology (pro- and anti-tumour) became a focus of translational medicine.
Combination approaches
Emerging preclinical research explores peptide combinations with immune checkpoint inhibitors (PD-1/PD-L1 antibodies). TA1 + anti-PD-1 combination data from murine tumour models has attracted significant interest, given the relatively benign safety profile of TA1 vs. checkpoint toxicity.
| Peptide | Oncology Application | Evidence Stage |
|---|---|---|
| Thymosin Alpha-1 | Immune adjunct in chemotherapy | Human trials |
| Epithalon | Anti-tumour, telomere support | Human pilot |
| BPC-157 | Chemo mucositis / organ protection | Preclinical |
| TB-500 | Cardiotoxicity / radiation recovery | Preclinical |
| GHK-Cu | Wound healing / antioxidant | Preclinical + in vitro |
| LL-37 | Direct anti-tumour (in vitro) | In vitro / animal |
| Selank | Immune restoration / anxiolytic | Preclinical |
The research described on this page warrants significant interpretive caution. The limitations below are not peripheral — they are central to understanding what these findings actually mean.
Most data is preclinical
The majority of findings cited above come from rodent models or cell culture studies. Rodent physiology, immune systems, and tumour biology differ substantially from humans. Many preclinical results have not translated to clinical benefit — this is a pattern, not an exception, in oncology drug development.
Heterogeneity of cancer
Cancer is not one disease. A peptide that shows anti-tumour activity in colorectal cancer cell lines may have no effect — or even promote growth — in breast or prostate cancer. Generalising findings across cancer types is a common and dangerous error in interpreting this literature.
Publication bias
Studies reporting positive preclinical results are far more likely to be published than null results. The peptide literature, particularly for compounds like BPC-157 and Epithalon, is heavily produced by a small number of research groups, which limits independent replication.
Timing and context matter
Some peptides may have opposing effects depending on the cancer type, stage, or immune context. LL-37 is the clearest example — it promotes tumour angiogenesis in ovarian cancer while suppressing growth in colorectal cancer. Use in the wrong context could theoretically worsen outcomes.
No established oncology protocols
There are no validated dosing protocols, administration schedules, or safety profiles for using these peptides in cancer patients alongside active chemotherapy. The preclinical evidence does not provide sufficient basis to extrapolate human protocols.
Interaction with chemotherapy agents
The interaction between these peptides and specific chemotherapy drugs (platinum compounds, taxanes, anthracyclines, alkylating agents, etc.) is largely uncharacterised. Potential for pharmacokinetic or pharmacodynamic interactions — beneficial or harmful — cannot be excluded.
Can peptides replace chemotherapy or cancer treatment?
No. No peptide described on this page is a substitute for established oncology treatment. The research discussed is entirely preclinical (animal models and cell culture) or limited to adjunctive roles in human trials. Cancer treatment decisions must be made by qualified oncologists based on established protocols.
Is Thymosin Alpha-1 approved anywhere as a cancer treatment?
TA1 (sold as Zadaxin) is approved in over 35 countries as an immune adjunct, including for some hepatitis-related liver cancers. It is not approved by the FDA or TGA, and in Australia it is available for research use only. Some Asian and European countries permit its clinical use alongside standard chemotherapy.
Is BPC-157 legal in Australia for research?
BPC-157 is not TGA-approved for human use and has no approved therapeutic indication in Australia. Capital Peptides supplies it strictly as a research chemical for in-vitro and preclinical research purposes, not for human consumption.
How does chemotherapy damage normal tissue and why might peptides help?
Most chemotherapy agents target rapidly dividing cells indiscriminately — including normal mucosal cells, bone marrow progenitors, hair follicles, and peripheral nerve tissue. Peptides like BPC-157, TB-500, and GHK-Cu have shown in preclinical models that they can accelerate repair of this collateral damage by stimulating local growth factor production, reducing inflammation, and promoting angiogenesis in injured tissue.
What is the difference between a cytoprotective peptide and an anti-tumour peptide?
Cytoprotective peptides (BPC-157, TB-500) primarily protect and repair normal tissue damaged by treatment — they do not directly target cancer cells. Anti-tumour peptides (LL-37, some GHK-Cu findings) show direct cytotoxic or growth-suppressive activity against cancer cells in laboratory models. Immune-modulatory peptides (TA1, Selank) work by enhancing the body's own immune response to tumour cells.
Can I use these peptides alongside conventional chemotherapy?
This question is strictly for your oncologist or treating physician. Some preclinical evidence suggests potential complementary mechanisms, but interactions with specific chemotherapy agents are not fully characterised. No information on this page constitutes medical advice, and these products are not for human use.
What peptides are most relevant to recovery from radiation therapy?
Preclinical research on radiation recovery has focused on TB-500 (bone marrow and mucosal regeneration), BPC-157 (intestinal epithelium repair after radiation enteritis), and Thymosin Alpha-1 (immune reconstitution following radiation-induced lymphopenia). These findings come from animal models and cannot be extrapolated directly to clinical use.
Is there human clinical data for any of these peptides in oncology?
Thymosin Alpha-1 has the most robust human clinical data, including published Phase II and III trials from China and Italy in hepatocellular carcinoma and lung cancer. Epithalon has limited small-scale human data from Russian research groups. BPC-157, TB-500, GHK-Cu, and LL-37 remain primarily at the preclinical stage for oncology applications.
Research compounds
Third-party COA verified. Research-grade lyophilised powder. Fast AU shipping.